SCHEMBL2376496

SCHEMBL2376496

Cc1cc(C(=O)N2CCCCC2)ccc1Br

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 13/20 0.77
TSHR P16473 2/20 0.77
ALDH1A1 P00352 4/20 0.59
KMT2A Q03164 2/20 0.57
PLA2G7 Q13093 1/20 0.56
CNR2 P34972 1/20 0.56
POLB P06746 1/20 0.56
ATM Q13315 1/20 0.56
MEN1 O00255 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
GFER P55789 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
RECQL P46063 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2378485 1.00 HPGD (0.77) HPGDTSHRALDH1A1KMT2APLA2G7
SCHEMBL848798 0.98 HPGD (0.77) HPGDTSHRALDH1A1KMT2APLA2G7
SCHEMBL9300442 0.95 HPGD (0.71) HPGDTSHRALDH1A1KMT2APLA2G7
SCHEMBL849340 0.86 HPGD (0.59) HPGDTSHRALDH1A1KMT2APOLB
SCHEMBL17689127 0.85 HPGD (0.73) HPGDTSHRALDH1A1KMT2APLA2G7
SCHEMBL2378109 0.84 HPGD (0.67) HPGDTSHRALDH1A1KMT2APOLB
SCHEMBL14314758 0.84 HPGD (0.68) HPGDTSHRALDH1A1KMT2APLA2G7
SCHEMBL850574 0.83 HSP90AA1 (0.59) HPGDTSHRALDH1A1KMT2ACNR2
SCHEMBL848003 0.83 HPGD (0.56) HPGDTSHRALDH1A1KMT2APLA2G7
SCHEMBL12569383 0.83 HPGD (0.73) HPGDTSHRALDH1A1KMT2APLA2G7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
CN-101501035-B Pyrimidine derivatives as PI3K inhibitors and uses thereof CHUGAI PHARMACEUTICAL CO LTD 2013-01-23 CN disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 HPGD 1383/4885TSHR 3412/4885ALDH1A1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.